{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "CCC",
      "Coronavirus",
      "HuCoV",
      "NL63",
      "OC43",
      "T cells",
      "common cold",
      "cross-reactivity",
      "epitopes",
      "sarbeco"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37295422",
  "DateCompleted": {
    "Year": "2023",
    "Month": "06",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "07",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "05",
        "Day": "29"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "101088",
      "10.1016/j.xcrm.2023.101088",
      "S2666-3791(23)00207-0"
    ],
    "Journal": {
      "ISSN": "2666-3791",
      "JournalIssue": {
        "Volume": "4",
        "Issue": "6",
        "PubDate": {
          "Year": "2023",
          "Month": "Jun",
          "Day": "20"
        }
      },
      "Title": "Cell reports. Medicine",
      "ISOAbbreviation": "Cell Rep Med"
    },
    "ArticleTitle": "Targets and cross-reactivity of human T\u00a0cell recognition of common cold coronaviruses.",
    "Pagination": {
      "StartPage": "101088",
      "MedlinePgn": "101088"
    },
    "Abstract": {
      "AbstractText": [
        "The coronavirus (CoV) family includes several viruses infecting humans, highlighting the importance of exploring pan-CoV vaccine strategies to provide broad adaptive immune protection. We analyze T\u00a0cell reactivity against representative Alpha (NL63) and Beta (OC43) common cold CoVs (CCCs) in pre-pandemic samples. S, N, M, and nsp3 antigens are immunodominant, as shown for severe acute respiratory syndrome 2 (SARS2), while nsp2 and nsp12 are Alpha or Beta specific. We further identify 78 OC43- and 87 NL63-specific epitopes, and, for a subset of those, we assess the T\u00a0cell capability to cross-recognize sequences from representative viruses belonging to AlphaCoV, sarbecoCoV, and Beta-non-sarbecoCoV groups. We find T\u00a0cell cross-reactivity within the Alpha and Beta groups, in 89% of the instances associated with sequence conservation >67%. However, despite conservation, limited cross-reactivity is observed for sarbecoCoV, indicating that previous CoV exposure is a contributing factor in determining cross-reactivity. Overall, these results provide critical insights in developing future pan-CoV vaccines."
      ],
      "CopyrightInformation": "Copyright \u00a9 2023 The Author(s). Published by Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Experimental Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, 16132 Genoa, Italy."
          }
        ],
        "LastName": "Tarke",
        "ForeName": "Alison",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "J. Craig Venter Institute, La Jolla, CA 92037, USA."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Yun",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA."
          }
        ],
        "LastName": "Methot",
        "ForeName": "Nils",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7290, USA."
          }
        ],
        "LastName": "Narowski",
        "ForeName": "Tara M",
        "Initials": "TM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA 6150, Australia."
          }
        ],
        "LastName": "Phillips",
        "ForeName": "Elizabeth",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA 6150, Australia."
          }
        ],
        "LastName": "Mallal",
        "ForeName": "Simon",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA."
          }
        ],
        "LastName": "Frazier",
        "ForeName": "April",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center of Excellence for Biomedical Research, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy; Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy."
          }
        ],
        "LastName": "Filaci",
        "ForeName": "Gilberto",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA."
          }
        ],
        "LastName": "Weiskopf",
        "ForeName": "Daniela",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA."
          }
        ],
        "LastName": "Dan",
        "ForeName": "Jennifer M",
        "Initials": "JM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7290, USA."
          }
        ],
        "LastName": "Premkumar",
        "ForeName": "Lakshmanane",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "J. Craig Venter Institute, La Jolla, CA 92037, USA; Department of Pathology, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: rscheuermann@jcvi.org."
          }
        ],
        "LastName": "Scheuermann",
        "ForeName": "Richard H",
        "Initials": "RH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: alex@lji.org."
          }
        ],
        "LastName": "Sette",
        "ForeName": "Alessandro",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. Electronic address: agrifoni@lji.org."
          }
        ],
        "LastName": "Grifoni",
        "ForeName": "Alba",
        "Initials": "A"
      }
    ],
    "GrantList": [
      {
        "GrantID": "75N93019C00065",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "75N93019C00076",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P01 AI168347",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cell Rep Med",
    "NlmUniqueID": "101766894",
    "ISSNLinking": "2666-3791"
  },
  "CommentsCorrectionsList": [
    {
      "RefSource": "bioRxiv. 2023 Jan 05;:",
      "PMID": "36656777"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "T-Lymphocytes"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cross Reactions"
    }
  ],
  "CoiStatement": "Declaration of interests A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group, and Guggenheim. L.J.I. has filed for patent protection for various aspects of T\u00a0cell epitope and vaccine design work."
}